Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1651 1657
This examiner grants 29% of resolved cases
Deepa Mishra has 81 resolved cases in Art Unit 1651. Her allowance rate is 29.6 percent, which is a low rate for Tech Center 1600. This baseline reflects a rigorous examination environment for the applications assigned to her docket.
The interview lift of 34.9 percent is quite high. This 34.9 percent lift suggests that interviews are a very effective tool for improving the 29.6 percent allowance rate. Practitioners should consider direct engagement as a primary strategy for overcoming rejections and moving toward a grant.
The median days to allowance is 1419. This long duration for 81 resolved cases indicates a difficult and slow prosecution process. The 1419 day median is a critical factor for applicants to consider when managing their expectations for pendency in Art Unit 1651.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17045605 | GINGIVITIS DIAGNOSTIC METHODS, USES AND KITS | Final Rejection | KONINKLIJKE PHILIPS N.V. |
| 17786149 | ENZYME ENHANCED ROOT UPTAKE OF AGROCHEMICAL ACTIVE COMPOUND | Final Rejection | BASF SE |
| 18394724 | SMALL-MOLECULE-ACTIVATED GLYCAN MODIFYING ENZYMES AND USES THEREOF | Non-Final OA | President and Fellows of Harvard College |
| 17265505 | PRENATAL PROBIOTIC FORMULATIONS | Non-Final OA | RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL |
| 16832347 | Method for Producing Nicotinamide Mononucleotide and Transformant Used in Said Method | Non-Final OA | Mitsubishi Chemical Corporation |
| 18709329 | METHOD FOR THE PRODUCTION OF HIGH PURITY BIOGASES FROM A LIGNOCELLULOSIC FEEDSTOCK | Final Rejection | THE PENN STATE RESEARCH FOUNDATION |
| 18709342 | SYSTEMS AND METHODS FOR THE PRODUCTION OF BIOGASES FROM A LIGNOCELLULOSIC FEEDSTOCK | Non-Final OA | THE PENN STATE RESEARCH FOUNDATION |
| 18915716 | METHODS FOR PREDICTING AUTOIMMUNITY POST GENE THERAPY | Non-Final OA | Children's Hospital Medical Center |
| 18457679 | RECOGNITION OF CELLULAR TARGET BINDING BY A BIOACTIVE AGENT USING INTRACELLULAR BIOLUMINESCENCE RESONANCE ENERGY TRANSFER | Non-Final OA | Promega Corporation |
| 18837311 | NOVEL THERAPEUTIC USES OF GARDNERELLA ENDOLYSINS | Non-Final OA | BioNTech SE |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy